|
Ranbaxy Laboratories Limited (RLL), along with its subsidiaries and associates operates as an integrated international pharmaceutical organization with businesses encompassing the entire value chain in the production, marketing and distribution of dosage forms and active pharmaceutical ingredients. It has manufacturing facilities in 11 countries, namely Brazil, China, India, Ireland, Japan, Malaysia, Nigeria, Romania, South Africa, the United States and Vietnam. Its major markets include the United States, India, Europe, Russia / CIS, Brazil and South Africa. The major products include, inter alia, Simvastatin, CoAmoxyclav, Amoxycillin, Ciprofloxacin, Isotretinon and Cephalexin. Its research and development activities are principally carried out at its facilities in Gurgaon, near New Delhi, India. RLL’s segments include Pharmaceuticals and Other businesses. In November 2008, Daiichi Sankyo Co., Ltd. completed the takeover of RLL by buying a 63.9% stake.
|
|
BSE Sensex
BOM:500359
